Glecaprevir/Pibrentasvir and Cyclosporine Interaction

Understanding the Glecaprevir/Pibrentasvir and Cyclosporine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Glecaprevir/Pibrentasvir belongs to the NS3/4A/NS5A Inhibitor (HCV) class and Cyclosporine belongs to the Calcineurin Inhibitor (Immunosuppressant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cyclosporine causes the levels of glecaprevir and pibrentasvir to increase in your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Glecaprevir/Pibrentasvir has 38 total documented interactions on file in this dataset, and Cyclosporine has 89. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination is not recommended if you take more than 100 mg of cyclosporine per day. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Glecaprevir/Pibrentasvir or Cyclosporine based on a web page, speak with your prescriber or pharmacist before making any change.